NIH-funded research NIH-funded research

Identifying blood markers to predict treatment response in rectal cancer patients

Official title: Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer

Funded at Research Inst of Fox Chase Can Ctr · NIH-11143949 · Data updated 2026-11-12

This study is looking at how a new blood test can help doctors figure out which patients with locally advanced rectal cancer will respond well to their treatment before they start, so they can tailor the therapy to each person and avoid unnecessary side effects.

More Rectal Cancer research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionResearch Inst of Fox Chase Can Ctr
NIH-funded
Lab location1 site (Philadelphia, United States)
Project startMay 1, 2022
Project endApril 30, 2027
Funding year2025
Award (this year)$470,000
NIH project number5UH3CA271230-04
Project IDNIH-11143949 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients diagnosed with locally advanced rectal cancer who are scheduled to receive neoadjuvant chemoradiation therapy.

Less likely to help

Patients with rectal cancer who are not receiving neoadjuvant chemoradiation therapy or those with early-stage disease may not benefit from this research.

What this research studies

This research focuses on patients with locally advanced rectal cancer who are undergoing neoadjuvant chemoradiation therapy. The goal is to develop and validate a blood test that can predict how well a patient will respond to this treatment. By analyzing specific biomarkers in blood samples, researchers aim to determine which patients are likely to benefit from the therapy and which may not respond at all. This approach seeks to make treatment more personalized and effective, potentially sparing some patients from unnecessary side effects of ineffective treatments.

Why it matters

Potential benefit: If successful, this research could lead to more personalized treatment plans for rectal cancer patients, improving outcomes and reducing unnecessary treatments.

How similar studies have gone: Previous research has shown promise in using blood-based biomarkers for predicting treatment responses in various cancers, suggesting that this approach may be viable.

Where this research is happening

  • Research Inst of Fox Chase Can Ctr
    Philadelphia, United States
    Active

Researchers

  • Principal investigator: Arora, Sanjeevani — Research Inst of Fox Chase Can Ctr
  • Study coordinator: Arora, Sanjeevani

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.